129 related articles for article (PubMed ID: 23105224)
1. Levels of plasma soluble complement receptor 1 (sCR1) in normal Indian adult population.
Sivasankar B; Raju KR; Anand V; Malu S; Padmanabhan S; Tiwari SC; Das N; Srivastava LM
Indian J Clin Biochem; 1999 Jul; 14(2):237-40. PubMed ID: 23105224
[TBL] [Abstract][Full Text] [Related]
2. Low levels of plasma soluble complement receptor type 1 in patients receiving thrombolytic therapy for acute myocardial infarction.
Karthikeyan G; Baalasubramanian S; Seth S; Das N
J Thromb Thrombolysis; 2007 Apr; 23(2):115-20. PubMed ID: 17131173
[TBL] [Abstract][Full Text] [Related]
3. Complement Receptor 1 (CR1, CD35) Polymorphisms and Soluble CR1: A Proposed Anti-inflammatory Role to Quench the Fire of "Fogo Selvagem" Pemphigus Foliaceus.
Oliveira LC; Kretzschmar GC; Dos Santos ACM; Camargo CM; Nisihara RM; Farias TDJ; Franke A; Wittig M; Schmidt E; Busch H; Petzl-Erler ML; Boldt ABW
Front Immunol; 2019; 10():2585. PubMed ID: 31824479
[TBL] [Abstract][Full Text] [Related]
4. Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases.
Di Bona D; Montalto G; Clemenza L; Bascone F; Accardo P; Bellavia D; Craxì A; Brai M
Clin Exp Immunol; 1998 Oct; 114(1):102-5. PubMed ID: 9764610
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes.
Pascual M; Duchosal MA; Steiger G; Giostra E; Pechère A; Paccaud JP; Danielsson C; Schifferli JA
J Immunol; 1993 Aug; 151(3):1702-11. PubMed ID: 8335953
[TBL] [Abstract][Full Text] [Related]
6. Soluble complement receptor type 1 (CD35) is released from leukocytes by surface cleavage.
Danielsson C; Pascual M; French L; Steiger G; Schifferli JA
Eur J Immunol; 1994 Nov; 24(11):2725-31. PubMed ID: 7957565
[TBL] [Abstract][Full Text] [Related]
7. Soluble complement receptor type 1 (CD35) in bronchoalveolar lavage of inflammatory lung diseases.
Hamacher J; Sadallah S; Schifferli JA; Villard J; Nicod LP
Eur Respir J; 1998 Jan; 11(1):112-9. PubMed ID: 9543279
[TBL] [Abstract][Full Text] [Related]
8. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway.
Scesney SM; Makrides SC; Gosselin ML; Ford PJ; Andrews BM; Hayman EG; Marsh HC
Eur J Immunol; 1996 Aug; 26(8):1729-35. PubMed ID: 8765013
[TBL] [Abstract][Full Text] [Related]
9. First Report of CR1 Polymorphisms and Soluble CR1 Levels Associated with Late Onset Alzheimer's Disease (LOAD) in Latin America.
Kretzschmar GC; Antoniazzi AAH; Oliveira LC; Nisihara RM; Petzl-Erler ML; de Souza RLR; Boldt ABW
J Mol Neurosci; 2020 Sep; 70(9):1338-1344. PubMed ID: 32388800
[TBL] [Abstract][Full Text] [Related]
10. Association of complement receptor 1 (CR1, CD35, C3b/C4b receptor) density polymorphism with glomerulonephritis in Indian subjects.
Katyal M; Tiwari SC; Kumar A; Dinda AK; Arora V; Kumar R; Das N
Mol Immunol; 2004 Apr; 40(18):1325-32. PubMed ID: 15072851
[TBL] [Abstract][Full Text] [Related]
11. CR1, CD35 in synovial fluid from patients with inflammatory joint diseases.
Sadallah S; Lach E; Lutz HU; Schwarz S; Guerne PA; Schifferli JA
Arthritis Rheum; 1997 Mar; 40(3):520-6. PubMed ID: 9082940
[TBL] [Abstract][Full Text] [Related]
12. Identification of membrane-bound CR1 (CD35) in human urine: evidence for its release by glomerular podocytes.
Pascual M; Steiger G; Sadallah S; Paccaud JP; Carpentier JL; James R; Schifferli JA
J Exp Med; 1994 Mar; 179(3):889-99. PubMed ID: 8113681
[TBL] [Abstract][Full Text] [Related]
13. The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4.
Gibb AL; Freeman AM; Smith RA; Edmonds S; Sim E
Biochim Biophys Acta; 1993 Jan; 1180(3):313-20. PubMed ID: 8422437
[TBL] [Abstract][Full Text] [Related]
14. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart.
Homeister JW; Satoh PS; Kilgore KS; Lucchesi BR
J Immunol; 1993 Feb; 150(3):1055-64. PubMed ID: 8423331
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of soluble complement receptor 1 in serum patients with liver diseases.
Sadallah S; Giostra E; Mentha G; Schifferli JA
Hepatology; 1996 Jul; 24(1):118-22. PubMed ID: 8707249
[TBL] [Abstract][Full Text] [Related]
16. Soluble complement receptor 1 is increased in patients with leukemia and after administration of granulocyte colony-stimulating factor.
Sadallah S; Lach E; Schwarz S; Gratwohl A; Spertini O; Schifferli JA
J Leukoc Biol; 1999 Jan; 65(1):94-101. PubMed ID: 9886251
[TBL] [Abstract][Full Text] [Related]
17. Inherited and Acquired Decrease in Complement Receptor 1 (CR1) Density on Red Blood Cells Associated with High Levels of Soluble CR1 in Alzheimer's Disease.
Mahmoudi R; Feldman S; Kisserli A; Duret V; Tabary T; Bertholon LA; Badr S; Nonnonhou V; Cesar A; Neuraz A; Novella JL; Cohen JHM
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30044434
[TBL] [Abstract][Full Text] [Related]
18. Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis.
Vriesendorp FJ; Flynn RE; Pappolla MA; Koski CL
Int J Neurosci; 1997 Dec; 92(3-4):287-98. PubMed ID: 9522271
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury.
Mulligan MS; Yeh CG; Rudolph AR; Ward PA
J Immunol; 1992 Mar; 148(5):1479-85. PubMed ID: 1311349
[TBL] [Abstract][Full Text] [Related]
20. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis.
Couser WG; Johnson RJ; Young BA; Yeh CG; Toth CA; Rudolph AR
J Am Soc Nephrol; 1995 May; 5(11):1888-94. PubMed ID: 7620086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
